Pure Global
NCT06234904

Study of IBR733 Cell Injection in Acute Myeloid Leukemia

An Open-label, Multi-center, Phase I Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IBR733 Cell Injection in Acute Myeloid Leukemia
Imbioray (Hangzhou) Biomedicine Co., Ltd.·Phase 1·ClinicalTrials.gov·biologicalNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acute Myeloid Leukemia
Drug/Device/Intervention
IBR733 Cell Injection
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Location
Suzhou, China
Timeline & enrollment
Phase
Phase 1
Start date
Feb 01, 2024
End date
Aug 01, 2025
Enrollment
18 participants
Primary outcome

Incidence of dose limiting toxicity (DLT),The incidence and severity of adverse events (AEs)

Summary

This is an open-label clinical study: phase Ia is the dose-escalation part, and phase Ib is
 the dose-expansion part. The phase Ia study is to evaluate the safety, tolerability,
 recommended phase II dose, pharmacokinetics, immunogenicity and preliminary efficacy of
 IBR733 cell injection in relapsed/refractory acute myeloid leukemia (AML).

ICD-10 classifications
Myeloid leukaemiaAcute myeloblastic leukaemia [AML]Myeloid leukaemia, unspecifiedAcute myelomonocytic leukaemiaAcute myeloid leukaemia with 11q23-abnormality
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06234904
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06234904 through Pure Global AI's free database. This Phase 1 trial is sponsored by Imbioray (Hangzhou) Biomedicine Co., Ltd. and is currently Not yet recruiting. The study focuses on Acute Myeloid Leukemia. Target enrollment is 18 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.